Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 19/20 | 0.51 |
| ▸ | BRAF | P15056 | 1/20 | 0.47 |
| ▸ | MAP2K2 | P36507 | 6/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1516527 | 0.91 | MAP2K1 (0.45) | MAP2K1BRAFMAP2K2 | |
| SCHEMBL18086455 | 0.90 | BRAF (0.48) | MAP2K1BRAF | |
| SCHEMBL9284438 | 0.90 | BRAF (0.48) | MAP2K1BRAFMAP2K2 | |
| SCHEMBL1516512 | 0.89 | BRAF (0.48) | MAP2K1BRAFMAP2K2 | |
| SCHEMBL15700928 | 0.84 | MAP2K1 (0.46) | MAP2K1MAP2K2 | |
| SCHEMBL13113736 | 0.84 | MAP2K1 (0.42) | MAP2K1BRAFMAP2K2 | |
| SCHEMBL13113727 | 0.84 | MAP2K1 (0.43) | MAP2K1BRAFMAP2K2 | |
| SCHEMBL13113251 | 0.83 | MAP2K1 (0.50) | MAP2K1MAP2K2 | |
| SCHEMBL13113732 | 0.83 | MAP2K1 (0.48) | MAP2K1MAP2K2 | |
| SCHEMBL1516486 | 0.82 | MAP2K1 (0.56) | MAP2K1MAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053211-A1 | TREATMENT OF PANCREATIC CANCER | ARDEA BIOSCIENCES, INC. (US) | 2012-03-01 | — | — | US | claimed |
| EP-2405907-A1 | TREATMENT OF PANCREATIC CANCER | Ardea Biosciences, Inc. (US) | 2012-01-18 | — | — | EP | claimed |
| WO-2010105082-A1 | TREATMENT OF PANCREATIC CANCER | ARDEA BIOSCIENCES, INC. (US) | 2010-09-16 | — | — | WO | claimed |
| EP-2175885-B1 | COMBINATIONS OF MEK INHIBITORS AND RAF KINASE INHIBITORS AND USES THEREOF | ARDEA BIOSCIENCES INC (US) | 2016-10-12 | — | — | EP | disclosed |
| US-20160271122-A1 | COMBINATIONS OF MEK INHIBITORS AND RAF KINASE INHIBITORS AND USES THEREOF | ARDEA BIOSCIENCES, INC. (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160271122-A1 | COMBINATIONS OF MEK INHIBITORS AND RAF KINASE INHIBITORS AND USES THEREOF | ARDEA BIOSCIENCES, INC. (US) | 2016-09-22 | — | — | US | disclosed |
| US-20150267258-A1 | BIOMARKERS FOR DETERMINING EFFECTIVE RESPONSE OF TREATMENTS OF HEPATOCELLULAR CARCINOMA (HCC) PATIENTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20150267258-A1 | BIOMARKERS FOR DETERMINING EFFECTIVE RESPONSE OF TREATMENTS OF HEPATOCELLULAR CARCINOMA (HCC) PATIENTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20150265679-A1 | METHOD OF REDUCING ADVERSE EFFECTS IN A CANCER PATIENT UNDREGOING TREATMENT WITH A MEK INHIBITOR | THE UNITED STATES OF AMERICA, AS REPRESENTED BY SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-09-24 | — | — | US | disclosed |
| US-9095581-B2 | Combinations of MEK inhibitors and Raf kinase inhibitors and uses thereof | ARDEA BIOSCIENCES, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-9095581-B2 | Combinations of MEK inhibitors and Raf kinase inhibitors and uses thereof | ARDEA BIOSCIENCES, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| WO-2010105082-A1 | TREATMENT OF PANCREATIC CANCER | ARDEA BIOSCIENCES, INC. (US) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010105082-A1 | TREATMENT OF PANCREATIC CANCER | ARDEA BIOSCIENCES, INC. (US) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010105082-A1 | TREATMENT OF PANCREATIC CANCER | ARDEA BIOSCIENCES, INC. (US) | 2010-09-16 | — | — | WO | disclosed |
| WO-2009018238-A1 | COMBINATIONS OF MEK INHIBITORS AND RAF KINASE INHIBITORS AND USES THEREOF | ARDEA BIOSCIENCES, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| EP-2012786-A2 | PYRIDONE SULFONAMIDES AND PYRIDONE SULFAMIDES AS MEK INHIBITORS | Ardea Biosciences, Inc. (US) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007121481-A2 | PYRIDONE SULFONAMIDES AND PYRIDONE SULFAMIDES AS MEK INHIBITORS | ARDEA BIOSCIENCES, INC. (US) | 2007-10-25 | — | — | WO | disclosed |
| US-20070244164-A1 | PYRIDONE SULFONAMIDES AND PYRIDONE SULFAMIDES AS MEK INHIBITORS | ARDEA BIOSCIENCES (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244164-A1 | PYRIDONE SULFONAMIDES AND PYRIDONE SULFAMIDES AS MEK INHIBITORS | ARDEA BIOSCIENCES (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244164-A1 | PYRIDONE SULFONAMIDES AND PYRIDONE SULFAMIDES AS MEK INHIBITORS | ARDEA BIOSCIENCES (US) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053211-A1 | TREATMENT OF PANCREATIC CANCER | KRAS, RNASE1, PKD1 | MAP2K1 1901/4885BRAF 951/4885MAP2K2 2897/4885 |
| US-20160271122-A1 | COMBINATIONS OF MEK INHIBITORS AND RAF KINASE INHIBITORS AND USES THEREOF | BRAF, RAF1, NRAS | MAP2K1 71/4885BRAF 1/4885MAP2K2 74/4885 |
| US-20150265679-A1 | METHOD OF REDUCING ADVERSE EFFECTS IN A CANCER PATIENT UNDREGOING TREATMENT WITH A MEK INHIBITOR | NRAS, BRAF, KRAS | MAP2K1 259/4885BRAF 2/4885MAP2K2 209/4885 |
| US-20150267258-A1 | BIOMARKERS FOR DETERMINING EFFECTIVE RESPONSE OF TREATMENTS OF HEPATOCELLULAR CARCINOMA (HCC) PATIENTS | NRAS, KRAS, TP53 | MAP2K1 110/4885BRAF 6/4885MAP2K2 116/4885 |
| US-20070244164-A1 | PYRIDONE SULFONAMIDES AND PYRIDONE SULFAMIDES AS MEK INHIBITORS | BRAF, PDXK, MAP3K20 | MAP2K1 38/4885BRAF 1/4885MAP2K2 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.